Volume 6, Issue 1 (Autumn 2013)                   Iranian Journal of Blood and Cancer 2013, 6(1): 51-53 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alavi S, Kaji Yazdi M, Arzanian M T. FMS-like Tyrosine Kinase-3 Mutation in a Child with Standard-risk ALL and Normal Karyotype. Iranian Journal of Blood and Cancer 2013; 6 (1) :51-53
URL: http://ijbc.ir/article-1-435-en.html
Abstract:   (8343 Views)
FMS-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. Mutations of FMS-like tyrosine kinase-3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphoblastic leukemia. The FMS-like tyrosine kinase-3 mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and are called internal tandem duplications. The other type of mutations in FMS-like tyrosine kinase-3 is located in the activation loop of the second tyrosine kinase domain. Multiple studies have shown that activating mutations of FMS-like tyrosine kinase-3 are common in blasts from patients with AML but are rarely found in adult patients with acute lymphoblastic leukemia. In addition, activating FLT3 mutations occur only rarely in T-ALL cases. Here we report a 3-year-old girl with ALL who had a mutation in FMS-like tyrosine kinase-3 / internal tandem duplications. Keywords: FMS-like tyrosine kinase-3, mutation, acute lymphoblastic leukemia, childhood.
Full-Text [PDF 486 kb]   (3087 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2013/06/7 | Accepted: 2013/09/15 | Published: 2013/11/30

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb